{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:04:07Z","timestamp":1790960647000,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","award":["CON-001559"],"award-info":[{"award-number":["CON-001559"]}],"id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.053","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T21:00:09Z","timestamp":1712005209000},"page":"3002-3008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda"],"prefix":"10.1016","volume":"42","author":[{"given":"Geofrey","family":"Kimbugwe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Vatrinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet A.","family":"Mwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kakuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Mpeirwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Logoose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimton","family":"Opio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-6793","authenticated-orcid":false,"given":"Mateus","family":"Kambale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-5272","authenticated-orcid":false,"given":"Janet","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca F.","family":"Grais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Marquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4801-0411","authenticated-orcid":false,"given":"Agnes","family":"Ssali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.053_b0005","unstructured":"History of Ebola Virus Disease (EVD) Outbreaks | History | Ebola (Ebola Virus Disease) | CDC [Internet]. 2022 [cit\u00e9 22 avr 2022]. Disponible sur: https:\/\/www.cdc.gov\/vhf\/Ebola\/history\/chronology.html."},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.053_b0010","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1046\/j.1365-3156.2002.00944.x","article-title":"An outbreak of Ebola in Uganda","volume":"7","author":"Okware","year":"2002","journal-title":"Trop Med Int Health TM IH d\u00e9c"},{"key":"10.1016\/j.vaccine.2024.03.053_b0015","doi-asserted-by":"crossref","first-page":"S761","DOI":"10.1093\/infdis\/jir294","article-title":"Filovirus outbreak detection and surveillance: lessons from Bundibugyo","volume":"204","author":"MacNeil","year":"2011","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.053_b0020","first-page":"1480","article-title":"Reemerging Sudan Ebola virus disease in Uganda, 2011","volume":"18","author":"Shoemaker","year":"2012","journal-title":"Emerg Infect Dis sept"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.053_b0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virol.2013.04.014","article-title":"Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012","volume":"442","author":"Albari\u00f1o","year":"2013","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10900-019-00711-z","article-title":"Exploration of Community Health Workers\u2019 views about in their role and support in Primary Health Care in Northern Cape, South Africa","volume":"45","author":"Ramukumba","year":"2020","journal-title":"J Commun Health"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.053_b0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0738-3991(01)00187-2","article-title":"The health promoting hospital (HPH): concept and development","volume":"45","author":"Pelikan","year":"2001","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.vaccine.2024.03.053_b0040","article-title":"Enablers and hindrances to health promotion and disease prevention practices among healthcare workers in Nelson Mandela Bay Municipality, South Africa","volume":"23","author":"Melariri","year":"2021","journal-title":"Prev Med Rep sept"},{"key":"10.1016\/j.vaccine.2024.03.053_b0045","unstructured":"World Health Organization. Health worker Ebola infections in Guinea, Liberia and Sierra Leone: a preliminary report 21 May 2015 [Internet]. World Health Organization; 2015 [cit\u00e9 22 avr 2022]. Report No.: WHO\/EVD\/SDS\/REPORT\/2015.1. Disponible sur: https:\/\/apps.who.int\/iris\/handle\/10665\/171823."},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.053_b0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/1099800403252603","article-title":"A current review of Ebola virus: pathogenesis, clinical presentation, and diagnostic assessment","volume":"4","author":"Casillas","year":"2003","journal-title":"Biol Res Nurs avr"},{"key":"10.1016\/j.vaccine.2024.03.053_b0055","doi-asserted-by":"crossref","unstructured":"Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, Kersti\u00ebns B, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epid\u00e9mies \u00e0 Kikwit. J Infect Dis 1999;179 Suppl 1:S76\u201386.","DOI":"10.1086\/514306"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.053_b0060","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1080\/17441692.2018.1552306","article-title":"\u00ab When I die, let me be the last. \u00bb community health worker perspectives on past Ebola and Marburg outbreaks in Uganda","volume":"14","author":"Englert","year":"2019","journal-title":"Glob Public Health ao\u00fbt"},{"issue":"7","key":"10.1016\/j.vaccine.2024.03.053_b0065","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/zph.12509","article-title":"Health workers\u2019 knowledge of zoonotic diseases in an endemic region of Western Uganda","volume":"65","author":"Benon","year":"2018","journal-title":"Zoonoses Public Health"},{"key":"10.1016\/j.vaccine.2024.03.053_b0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2024.03.053_b0075","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSV\u0394G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.053_b0080","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1740774518780678","article-title":"EBOVAC-salone: lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country","volume":"15","author":"Mooney","year":"2018","journal-title":"Clin Trials Lond Engl"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.053_b0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/21645515.2017.1264755","article-title":"EBOVAC1 consortium. a two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks","volume":"13","author":"Shukarev","year":"2017","journal-title":"Hum Vaccines Immunother"},{"issue":"9984","key":"10.1016\/j.vaccine.2024.03.053_b0090","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2024.03.053_b0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.conctc.2016.06.008","article-title":"Beating the odds: successful establishment of a phase II\/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak","volume":"4","author":"Doe-Anderson","year":"2016","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1740774515621037","article-title":"Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges","volume":"13","author":"Kennedy","year":"2016","journal-title":"Clin Trials Lond Engl"},{"issue":"10068","key":"10.1016\/j.vaccine.2024.03.053_b0105","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"The Lancet"},{"issue":"31","key":"10.1016\/j.vaccine.2024.03.053_b0110","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.vaccine.2020.04.066","article-title":"Humoral and cellular immune response induced by rVSV\u0394G-ZEBOV-GP vaccine among frontline workers during the 2013\u20132016 West Africa Ebola outbreak in Guinea","volume":"38","author":"Boum","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.03.053_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled Phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.053_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055596","article-title":"Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo","volume":"12","author":"Watson-Jones","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13063-021-05035-9","article-title":"Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries","volume":"22","author":"Badio","year":"2021","journal-title":"Trials"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.053_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005093","article-title":"Containing Ebola at the source with ring vaccination","volume":"10","author":"Merler","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.03.053_b0150","unstructured":"Tactics and strategies for managing Ebola outbreaks and the salience of immunization [Internet]. [cit\u00e9 22 avr 2022]. Disponible sur: https:\/\/www.hindawi.com\/journals\/cmmm\/2015\/736507\/."},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.053_b0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.vaccine.2016.12.019","article-title":"Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone","volume":"35","author":"Camacho","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.053_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152438","article-title":"Predicting and evaluating the epidemic trend of Ebola virus disease in the 2014\u20132015 outbreak and the effects of intervention measures","volume":"11","author":"Guo","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.053_b0165","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(20)30016-5","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0170","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2020.1829829","article-title":"Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda","volume":"13","author":"Kitonsa","year":"2020","journal-title":"Glob Health Action"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.053_b0175","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4161\/hv.24657","article-title":"Vaccine hesitancy: an overview","volume":"9","author":"Dub\u00e9","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12992-020-00548-5","article-title":"Uganda\u2019s experience in Ebola virus disease outbreak preparedness, 2018\u20132019","volume":"16","author":"Aceng","year":"2020","journal-title":"Glob Health"},{"key":"10.1016\/j.vaccine.2024.03.053_b0185","unstructured":"MRC\/UVRI and LSHTM Uganda Research Unit. An open-label, single arm study to provide additional information on immunogenicity and safety of Ad26.ZEBOV\/MVA-BN-Filo [Internet]. clinicaltrials.gov; 2021 mai [cit\u00e9 21 avr 2022]. Report No.: NCT04028349. Disponible sur: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04028349."},{"key":"10.1016\/j.vaccine.2024.03.053_b0190","unstructured":"Ebola Vaccine Regimen Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) [Internet]. [cit\u00e9 3 mai 2022]. Disponible sur: https:\/\/www.precisionvaccinations.com\/vaccines\/Ebola-vaccine-regimen-zabdeno-ad26zebov-and-mvabea-mva-bn-filo."},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.053_b0195","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"key":"10.1016\/j.vaccine.2024.03.053_b0200","unstructured":"Helena Priest PR. An overview of three different approaches to the interpretation of qualitative data. Part 1: theoretical issues [Internet]. Nurse Researcher; [cit\u00e9 23 avr 2022]. Disponible sur: https:\/\/journals.rcni.com\/doi\/abs\/10.7748\/nr2002.10.10.1.30.c5877."},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.053_b0205","first-page":"5","article-title":"Content analysis: concepts, methods and applications","volume":"4","author":"Cavanagh","year":"1997","journal-title":"Nurse Res"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","article-title":"The qualitative content analysis process","volume":"62","author":"Elo","year":"2008","journal-title":"J Adv Nurs avr"},{"key":"10.1016\/j.vaccine.2024.03.053_b0215","series-title":"The SAGE handbook of qualitative research","first-page":"785 p.","author":"Denzin","year":"2011"},{"issue":"48","key":"10.1016\/j.vaccine.2024.03.053_b0220","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1016\/j.vaccine.2019.09.094","article-title":"Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea","volume":"37","author":"Grantz","year":"2019","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.053_b0225","article-title":"Could the decision of trial participation precede the informed consent process? Evidence from Burkina Faso","volume":"8","author":"Toe","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.053_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/3563534","article-title":"Motivations, understanding, and voluntariness in international randomized trials","volume":"27","author":"Kass","year":"2005","journal-title":"IRB"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.053_b0235","first-page":"37","article-title":"Why do individuals agree to enrol in clinical trials? A qualitative study of health research participation in Blantyre, Malawi","volume":"20","author":"Mfutso-Bengo","year":"2008","journal-title":"Malawi Med J J Med Assoc Malawi"},{"issue":"49 Pt B","key":"10.1016\/j.vaccine.2024.03.053_b0240","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1016\/j.vaccine.2017.06.026","article-title":"Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: results of a national household survey","volume":"35","author":"Irwin","year":"2017","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2024.03.053_b0245","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.vaccine.2019.03.004","article-title":"Ebola epidemic in war-torn Democratic Republic of Congo, 2018: acceptability and patient satisfaction of the recombinant Vesicular stomatitis virus - Zaire Ebolavirus vaccine","volume":"37","author":"Kasereka","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.053_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003838","article-title":"Acceptability and willingness-to-pay for a hypothetical Ebola virus vaccine in Nigeria","volume":"9","author":"Ughasoro","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.03.053_b0255","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1080\/21645515.2018.1480236","article-title":"Willingness to get vaccinated against Ebola: a mapping of Guinean people positions","volume":"14","author":"Kpanake","year":"2018","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/phn.12822","article-title":"Nurses\u2019 experiences of their decision-making process when participating in clinical trials during the 2014\u20132016 West African Ebola crisis","volume":"38","author":"Nguyen","year":"2021","journal-title":"Public Health Nurs Boston Mass"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.053_b0265","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.vaccine.2019.01.046","article-title":"Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014\u20132015 Ebola outbreak in Sierra Leone","volume":"37","author":"Jalloh","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.053_b0270","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/inthealth\/ihz097","article-title":"\u00ab When you welcome well, you vaccinate well \u00bb: a qualitative study on improving vaccination coverage in urban settings in Conakry, Republic of Guinea","volume":"13","author":"Gil Cuesta","year":"2021","journal-title":"Int Health"},{"key":"10.1016\/j.vaccine.2024.03.053_b0275","unstructured":"Embrace the facts about vaccines, not the myths [Internet]. [cit\u00e9 23 avr 2022]. Disponible sur: https:\/\/www.who.int\/news-room\/commentaries\/detail\/embrace-the-facts-about-vaccines-not-the-myths."},{"key":"10.1016\/j.vaccine.2024.03.053_b0280","unstructured":"Vaccines and immunization: Myths and misconceptions [Internet]. [cit\u00e9 23 avr 2022]. Disponible sur: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/vaccines-and-immunization-myths-and-misconceptions."},{"key":"10.1016\/j.vaccine.2024.03.053_b0285","unstructured":"Addressing misconceptions on measles vaccination [Internet]. European Centre for Disease Prevention and Control. [cit\u00e9 23 avr 2022]. Disponible sur: https:\/\/www.ecdc.europa.eu\/en\/measles\/prevention-and-control\/addressing-misconceptions-measles."},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.053_b0290","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.socscimed.2006.02.018","article-title":"Where techno-science meets poverty: medical research and the economy of blood in the Gambia, West Africa","volume":"63","author":"Fairhead","year":"2006","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2024.03.053_b0295","unstructured":"Content and Design Attributes of Antivaccination Web Sites | Vaccination | JAMA | JAMA Network [Internet]. [cit\u00e9 5 mai 2022]. Disponible sur: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/195044."},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0300","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1186\/s12889-016-3799-x","article-title":"Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone","volume":"16","author":"Enria","year":"2016","journal-title":"BMC Public Health"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.053_b0305","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jclinepi.2005.09.002","article-title":"Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination","volume":"58","author":"Mills","year":"2005","journal-title":"J Clin Epidemiol"},{"issue":"9 Suppl","key":"10.1016\/j.vaccine.2024.03.053_b0310","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/1097-0142(19941101)74:9+<2687::AID-CNCR2820741817>3.0.CO;2-B","article-title":"Clinical trial participation. Viewpoints from racial\/ethnic groups","volume":"74","author":"Roberson","year":"1994","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.053_b0315","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMp1508413","article-title":"Community Trust and the Ebola Endgame","volume":"373","author":"Dhillon","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.053_b0320","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.socscimed.2008.02.003","article-title":"Taking social relationships seriously: Lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast","volume":"67","author":"Gikonyo","year":"2008","journal-title":"Soc Sci Med"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.053_b0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040073","article-title":"What led to the Nigerian boycott of the polio vaccination campaign?","volume":"4","author":"Jegede","year":"2007","journal-title":"PLOS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0330","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13063-019-3487-0","article-title":"Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context","volume":"20","author":"Lhomme","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/17441692.2019.1632368","article-title":"Conceptions within misconceptions: pluralisms in an Ebola vaccine trial in West Africa","volume":"15","author":"Alenichev","year":"2020","journal-title":"Glob Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.053_b0340","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0277-9536(98)00317-7","article-title":"An evaluation of the informed consent procedure used during a trial of a Haemophilus influenzae type B conjugate vaccine undertaken in The Gambia","volume":"48","author":"Leach","year":"1999","journal-title":"West Africa. Soc Sci Med"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.053_b0345","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/tmi.12288","article-title":"Informed consent comprehension in African research settings","volume":"19","author":"Afolabi","year":"2014","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2024.03.053_b0350","doi-asserted-by":"crossref","unstructured":"Informed consent and participant perceptions of influenza vaccine trials in South Africa | J Med Ethics [Internet]. [cit\u00e9 5 mai 2022]. Disponible sur: https:\/\/jme.bmj.com\/content\/31\/12\/727.","DOI":"10.1136\/jme.2004.009910"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.053_b0355","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijlp.2005.09.001","article-title":"Misconceived bioethics?: the misconception of the \u201ctherapeutic misconception\u201d","volume":"29","author":"Belkin","year":"2006","journal-title":"Int J Law Psychiatry"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0360","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12910-015-0073-1","article-title":"Volunteer experiences and perceptions of the informed consent process: lessons from two HIV clinical trials in Uganda","volume":"16","author":"Ssali","year":"2015","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.vaccine.2024.03.053_b0365","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.conctc.2017.05.007","article-title":"Reasons for participating in a randomised clinical trial: the volunteers\u2019 voices in the COSTOP trial in Uganda","volume":"7","author":"Ssali","year":"2017","journal-title":"Contemp Clin Trials Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0370","first-page":"78","article-title":"Ethical and practical considerations arising from community consultation on implementing controlled human infection studies using Schistosoma mansoni in Uganda","volume":"33","author":"Egesa","year":"2022","journal-title":"Glob Bioeth Probl Bioet"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.053_b0375","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/vaccines9020177","article-title":"Botched Ebola vaccine trials in Ghana: an analysis of discourses in the media","volume":"9","author":"Thompson","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.053_b0380","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/pls.2020.1","article-title":"Politics and trust in Ebola vaccine trials. The case of Ghana","volume":"39","author":"Aggrey","year":"2020","journal-title":"Polit Life Sci J Assoc Polit Life Sci"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400358X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400358X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:54:47Z","timestamp":1725688487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2400358X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":76,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X2400358X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}